# Strategic Feedback — GPT-5.2

**Role:** Journal editor (AER perspective)
**Model:** openai/gpt-5.2
**Timestamp:** 2026-03-05T17:37:02.782968
**Route:** OpenRouter + LaTeX
**Tokens:** 16784 in / 3019 out
**Response SHA256:** 23e6b173d6e7c656

---

## 1. THE ELEVATOR PITCH (Most Important)

**What the paper is about (2–3 sentences).**  
This paper asks whether state “Right-to-Try” (RTT) laws—designed to let terminally ill patients access investigational drugs outside randomized trials—disrupted the U.S. clinical trial system by reducing trial siting and enrollment. Using the full ClinicalTrials.gov registry and staggered state adoption, it finds precisely estimated near-zero effects on Phase II/III trial sites, planned enrollment, and (if anything) a small, imprecise *increase* in terminal-condition trials. A busy economist should care because RTT is an archetype of highly salient, low-implementation policy: the paper is effectively about when politically powerful “regulatory shocks” are economically non-binding, and how markets respond to symbolic legislation.

**Does the paper articulate this pitch clearly in the first two paragraphs?**  
Mostly yes: the first two paragraphs set up RTT, the industry’s stated concern (enrollment displacement and site relocation), and the central empirical question. What’s missing is a crisp “why economists should care” hook in paragraph 2—right now the broader stakes (innovation markets / symbolic policy / expectations) arrive later.

**What the first two paragraphs should say instead (the pitch the paper should have).**  
> Between 2014 and 2018, most U.S. states adopted “Right-to-Try” laws intended to bypass the FDA’s expanded-access process for terminal patients. Opponents—especially pharmaceutical firms—argued these laws would undermine drug innovation by diverting patients out of randomized clinical trials and pushing sponsors to move trial sites away from adopting states.  
>  
> This paper tests whether a highly salient but weakly enforceable regulation can nevertheless move an innovation market: do clinical trials respond to RTT through substitution, perceived risk, or regulatory uncertainty? Using the universe of ClinicalTrials.gov trials and staggered state adoption, I show RTT produced precisely estimated null effects on trial siting and enrollment, ruling out economically meaningful disruption.

---

## 2. CONTRIBUTION CLARITY

**Contribution in one sentence.**  
The paper provides the first registry-wide causal evidence that state Right-to-Try laws—despite intense debate—did not measurably change clinical trial siting, planned enrollment, or trial composition in adopting states.

**Is the contribution clearly differentiated from the closest 3–4 papers?**  
Only partially. The introduction names broad areas (FDA regulation, trial geography, RTT legal/bioethics) but does not sharply distinguish the paper from: (i) work on Expanded Access/compassionate use, (ii) studies on determinants of trial location and recruitment, and (iii) “policy salience vs implementation” papers in political economy/public economics. The “first causal evidence” claim will be credible only if the intro clearly maps the near-neighbor empirical papers and explains why RTT is a distinct object (state-level, symbolic, low take-up, and targeting terminal conditions).

**World vs literature framing?**  
It is closer to a *world* question than a “gap in the literature” question, which is good. The strongest version is: *How do innovation markets respond to salient but non-binding regulation?* The current text gestures at “symbolic legislation” late in the intro; that should be elevated to the main framing rather than the third contribution bullet.

**Could a smart economist explain what’s new after reading the intro?**  
They could say: “It’s a staggered DiD showing RTT didn’t matter for clinical trials.” That is clear, but it risks sounding like “another DiD paper with a null.” To make it feel genuinely new, the intro needs to sell (a) why RTT is a high-stakes innovation-market test case, and (b) why a *precise null* changes beliefs (about firm claims in policy debates, about the conditions under which regulation affects R&D inputs, about symbolic laws).

**What would make the contribution bigger (specific levers)?**
1. **Reframe outcomes around innovation-market inputs and margins that sponsors actually optimize.** Site counts are fine, but “trial starts” vs “trial locations,” sponsor type, multi-state footprint, and timing (delays/deferrals) are closer to an innovation production function story than simple counts.  
2. **Lean harder into “upper bounds” and belief updating.** The paper already has an MDE; the bigger contribution is: *we can rule out effects of the magnitude invoked in Congressional/state debates.* Quote the claimed magnitudes and explicitly benchmark the ruled-out range to those claims.  
3. **Make the symbolic-legislation mechanism test more explicit.** If the premise is “effects could operate via expectations/uncertainty even with near-zero take-up,” then the paper should pre-commit (in the narrative) to what evidence would look like under expectations/uncertainty (e.g., short-run sponsor avoidance around adoption; stronger effects in early-adopter periods; sponsor sensitivity by publicly traded firms; or by trial competitiveness areas like oncology).

---

## 3. LITERATURE POSITIONING

**Closest neighbors (3–5).**  
The paper cites some but should more explicitly position against a tight set such as:
- **Clinical trial markets / geography / recruitment:** papers on site location trends and recruitment constraints (Thiers et al. is cited; there are also economics-adjacent health/innovation papers on trial location choice and global outsourcing).  
- **R&D and regulation:** classic FDA/regulatory timing and drug development (DiMasi; Berndt—cited), plus newer economics on regulation-induced R&D reallocation.  
- **Stated vs revealed preferences / strategic rhetoric in policy debates:** political economy/public choice literatures on lobbying claims, “fear of regulation” narratives, and regulatory theater.  
- **Symbolic/non-binding policy and compliance:** economics papers on low-enforcement statutes, “laws on the books” vs “laws in action,” and policy salience with weak treatment intensity.

(As editor, I’d expect the eventual revision to name at least 2–3 *economics* anchor papers more directly aligned with “non-binding regulation / low take-up” rather than relying on political science classics alone.)

**How should it position relative to those neighbors?**  
Build and discipline them, not “attack.” The message is: *here is a clean, high-salience case where the market did not respond; that helps bound models of regulatory uncertainty and the credibility of industry warnings.* The paper should explicitly say: “If even RTT didn’t move trials, then under what institutional features would we expect trial markets to move?” That turns a null into a framework contribution.

**Too narrow or too broad right now?**  
Slightly narrow in *audience*: it reads like a well-executed policy evaluation in health/IO of pharma, with “symbolic legislation” appended. For AER-level positioning, it should be broadened upward: regulation and innovation, political economy of policy debates, and when “threatened disruption” is cheap talk.

**What literature does it seem unaware of? What fields should it speak to?**  
- **Innovation economics** on R&D input substitution and policy risk.  
- **Political economy of regulation**: strategic communication by regulated industries; credibility of claims; information and persuasion in legislative processes.  
- **Implementation / state capacity**: laws that change nominal rights but not practical access; “paper tigers.”  
Right now, the paper cites Edelman/Mayhew but does not connect to the modern economics conversation on state capacity, enforcement, and administrative burden.

**Is it having the right conversation?**  
It could be. The most AER-relevant conversation is not “RTT specifically,” but “innovation markets under symbolic or weakly implemented regulation”—RTT is the empirical vehicle.

---

## 4. NARRATIVE ARC

**Setup (world before).**  
RTT spreads rapidly; firms and bioethicists warn it could harm the clinical trial pipeline; policymakers argue over access vs innovation externalities.

**Tension (puzzle/gap).**  
Despite the political intensity and industry opposition, it’s unclear whether RTT actually changed the clinical trial market—or whether it was symbolic and non-binding.

**Resolution (findings).**  
No detectable effects on trial sites or planned enrollment; effects are tightly bounded.

**Implications (why change beliefs/behavior).**  
The clinical trial system appears resilient to this particular form of deregulatory, voluntary-access law; and industry warnings about disruption in this debate were not borne out.

**Evaluation of narrative arc.**  
The arc exists and is readable. The weak link is the *implications*: the paper sometimes concludes “fears were unfounded,” but the AER-level implication needs to be: *when and why do salient regulatory changes fail to move innovation inputs?* That is a generalizable claim; “RTT didn’t matter” is not enough on its own.

**If it’s a collection of results looking for a story, what story should it tell?**  
Not quite a collection—but it should commit to a single story: **RTT as a test of “regulatory theater” in innovation markets**, where the treatment is high salience but low constraint, and the paper’s job is to discipline expectations-based mechanisms.

---

## 5. THE "SO WHAT?" TEST

**Dinner-party lead fact.**  
“Thirty-eight states passed Right-to-Try laws amid claims they’d disrupt clinical trials—but using the full U.S. trial registry, you can rule out even mid-single-digit effects on trial siting and enrollment.”

**Lean in or phones?**  
Economists will lean in *if* the story is framed as: “this is a rare precisely estimated null that adjudicates a major innovation-policy argument and provides an upper bound on regulatory-uncertainty effects.” They’ll reach for phones if it’s framed as: “another policy didn’t do much.”

**Follow-up question they’d ask.**  
“If it didn’t move trials, is that because RTT was non-binding (no manufacturer participation), because firms anticipated/understood it, or because trials are geographically sticky—and can you show which margin is decisive?”

**Is the null interesting, or does it feel like a failed experiment?**  
It *can* be interesting because it is precisely estimated and politically salient; but the paper must treat the null as a positive object: a bound on disruption and a test of expectations/uncertainty channels. The current draft is close, but it still occasionally reads as “we checked, nothing happened” rather than “we learned something general about policy salience vs economic constraint.”

---

## 6. STRUCTURAL SUGGESTIONS

1. **Move the “symbolic legislation / why null matters” up.** Right now the most AER-relevant motivation appears after the main estimates and in the contribution bullets; it should be in the first page.  
2. **Shorten institutional background; sharpen to what matters for economic mechanisms.** The background is competent but long; it should be more surgical: what makes RTT plausibly disruptive, and what makes it plausibly non-binding.  
3. **Front-load one flagship figure/table and one benchmark claim.** The main ATT table plus an event-study figure is enough early; then benchmark the ruled-out effect sizes to the magnitudes invoked by opponents (ideally with direct quotes or quantitative claims).  
4. **De-emphasize DiD-credibility salesmanship in the main text.** The intro currently spends real estate asserting robustness (Bacon weights, RI, Rambachan–Roth). For AER positioning, that material can live mostly in an appendix or a shorter “design summary” box; keep the main text focused on economic interpretation and implications.  
5. **Conclusion: add “general lesson” and conditions for non-null effects.** The current conclusion is readable but could do more to generalize: what features (mandatory provision, liability shields, reporting requirements, insurance/payment rules) would likely generate effects.

---

## 7. WHAT WOULD MAKE THIS AN AER PAPER?

**The gap vs an AER-exciting paper (top 10 in field).**  
Right now this is a strong, careful null result on a salient policy—publishable in good field outlets and potentially a general-interest outlet *if* the framing lands. The main distance to AER is **ambition/framing**: the paper needs to be unmistakably about **innovation markets under non-binding regulation and the credibility of policy-economy claims**, not primarily about a specific health law.

- **Framing problem:** moderate. The ingredients are there, but the general-interest stakes need to be the organizing principle from page 1.  
- **Scope problem:** mild. Outcomes are sensible, but one or two additional “market response” margins that map directly to sponsor optimization (timing/delays, footprint concentration, multi-site breadth) would make the result harder to dismiss as narrow.  
- **Novelty problem:** moderate risk. “RTT has no effect” is not inherently a top-journal novelty; “precisely bounding the market impact of symbolic legislation in an innovation pipeline” is more novel.  
- **Ambition problem:** moderate. The draft is method-forward and robustness-forward; AER needs mechanism-forward and implication-forward.

**Single most impactful advice (if the author changes only one thing).**  
Rewrite the introduction and discussion to make RTT a *case study of non-binding regulation in innovation markets*, and explicitly derive (then test) predictions for expectation/uncertainty channels—so the paper’s headline becomes a general lesson with RTT as the vehicle, not RTT as the destination.

---

### Strategic Assessment

- **Current framing quality:** Adequate  
- **Contribution clarity:** Somewhat fuzzy  
- **Literature positioning:** Could be stronger  
- **Narrative arc:** Serviceable  
- **AER distance:** Medium  
- **Single biggest improvement:** Reframe the paper around a general question—when does salient but weakly enforceable regulation move innovation-market behavior?—and organize the evidence as a direct test of expectations/uncertainty mechanisms rather than as a “null DiD” on one policy.